Metabolic fate of pitavastatin, a new inhibitor of HMG-CoA reductase: Human UDP-glucuronosyltransferase enzymes involved in lactonization

Xenobiotica

Volumn 33, Issue 1, 2003, Pages 27-41

  Fujino, H ^a   Yamada, I ^a   Shimada, S ^a   Yoneda, M ^a   Kojima, J ^a  

^a KOWA COMPANY LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCURONOSYLTRANSFERASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LACTONE; PITAVASTATIN; URIDINE DIPHOSPHATE GLUCURONIC ACID;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG ISOLATION; DRUG METABOLISM; DRUG STABILITY; GLUCURONIDATION; HUMAN; HUMAN TISSUE; HYDROLYSIS; LIVER MICROSOME; METABOLISM; NONHUMAN;

BIOTRANSFORMATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; GLUCURONOSYLTRANSFERASE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INDICATORS AND REAGENTS; LACTONES; MICROSOMES, LIVER; QUINOLINES;

ANIMALIA;

EID: 0037235204     PISSN: 00498254     EISSN: None     Source Type: Journal    
DOI: 10.1080/0049825021000017957     Document Type: Article

References (33)

1. Alberts, A. W., 1990, Lovastatin and simvastatin inhibitor of HMG-CoA reductase and cholesterol biosynthesis. Cardiology, 77, 14-21.
2. Aoki, T., Nishimura, H., Nakagawa, S., Kojima, J., Suzuki, H., Tamaki, T., Wada, Y., Yokoo, N., Sato, F., Kimata, H., Kitahara, M., Toyoda, K., Sakashita, M. and Saito, Y., 1997, Pharmacological profile of novel synthetic inhibitor of 3-hydroxy-3-methylglutaryl-coenzme A reductase. Arzneim Forsch/Drug Research, 47, 904-909.
3. Baba, S., Terasawa, Y., Kimata, H., Shinohara, Y., Akira, K. and Hasegawa, H., 1994, Application of radioluminography to off-line counting of radioactivity in high-performance liquid chromatographic elutes. Journal of Chromatography (A), 663, 35-41.
4. Boberg, M., Angerbauer, R., Kanhai, W. K., Karl, W., Kern, A., Radtke, M. and Steinke, W., 1998, Biotransformation of cerivastatin in mice, rats, and dogs in vivo. Drug Metabolism and Disposition, 26, 640-652.
5. Brown, B. G., Zhao, X. Q., Sacco, D. E. and Albers, J. J., 1993, Lipid lowering and plaque regression: New insights into prevention of plaque disruption and clinical events in coronary disease. Circulation, 87, 1781-1791.
6. Burchell, B., Brierley, C. H. and Rance, D., 1995, Specificity of human UDP-glucuronosyltransferases and xenobiotic glucuronidation. Life Sciences, 57, 1819-1831.
7. Christians, U., Jacobsen, W. and Floren, L., 1998, Metabolism and drug interactions 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor in transplant patients: Are the statins mechanistically similar? Pharmacology and Therapy, 80, 1-34.
8. Dain, J. G., Fu, E., Gorski, J., Nicoletti, J. and Scallen, T. J., 1993, Biotransformation of fluvastatin sodium in humans. Drug Metabolism and Disposition, 21, 567-572.
9. Ding, A., Zia-Amirhosseini, P., McDonagh, A. F., Burlingame, A. L. and Benet, L. Z., 1995, Reactivity of tolmetin glucuronide with human serum albumin: Identification of binding sites and mechanism of reaction by tandem mass spectrometry. Drug Metabolism and Disposition, 23, 369-376.
10. Faed, E. M., 1984, Properties of acyl glucuronides: Implications for studies of the pharmacokinetics and metabolism of acidic drugs. Drug Metabolism Reviews, 15, 1213-1249.
11. Fischer, V., Johanson, L., Heitz, F., Tullman, R., Graham, E., Baldeck, J. P. and Robinson, W. T., 1999, The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor fluvastatin: Effect on human cytochrome P-450 and implications for metabolic drug interactions. Drug Metabolism and Disposition, 27, 410-416.
12. Fujino, H., Kojima, J., Yamada, Y., Kanda, H. and Kimata, H., 1999a, Studies on the metabolic fate of NK-104, a new inhibitor of HMG-CoA reductase (4):Interspecies variation in laboratory animals and humans. Xenobiotics and Metabolic Disposition, 14, 79-91.
13. Fujino, H., Yamada, I., Kojima, J., Hirano, M., Matsumoto, H. and Yoneda, M., 1999b, Studies on the metabolic fate of NK-104, a new inhibitor HMG-CoA reductase (5): In vitro metabolism and plasma protein binding in animals and human. Xenobiotics and Metabolic Disposition, 14, 415-424.
14. Fujino, H., Yamada, I., Shimada, S. and Yoneda, M., 2001, Simultaneous determination of taxol and its metabolites in microsomal samples by a simple thin layer chromatography assay-inhibitory effect of NK-104, a new inhibitor of HMG-CoA reductase. Journal of Chromatography (B), 757, 143-150.
15. Fujino, H., Yamada, I., Shimada, S. and Yoneda, M., 2002, The metabolic fate of pitavastatin (NK-104), a new inhibitor of HMG-CoA reductase: Effects on drug-metabolizing systems in rats and humans. Arzneim Forsch/Drug Research (in press).
16. Havel, R. J. and Rapaport, E., 1995, Management of primary hyperlipidemia. New England Journal of Medicine, 332, 1301-1307.
17. Ishigami, M., Honda, T., Takasaki, W., Ikeda, T., Komai, T., Ito, K. and Sugiyama, Y., 2001, A comparison of the effects of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors on the CYP3A4-dependent oxidation of mexazolam in vitro. Drug Metabolism and Disposition, 29, 282-288.
18. Jacobsen, W., Kuhn, B., Soldner, A., Kirchner, G., Sewing, K. F., Kollman, P. A., Benet, L. Z. and Christians, U., 2000, Lactonization is the critical first step in the disposition of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor atorvastatin. Drug Metabolism and Disposition, 28, 1369-1378.
19. Kajinami, K., Koizumi, J., Ueda, K., Miyamoto, S., Takegoshi, T. and Mabuchi, H., 2000b, Effect of NK-104, a new hydroxymethylglutaryl-coenzyme reductase inhibitor, on low density lipoprotein cholesterol in heterozygous familial hypercholesterolemia. Hokuriku NK-104 study group. American Journal of Cardiology, 15, 178-183.
20. Kajinami, K., Mabuchi, H. and Saito, Y., 2000a, NK-104, a novel synthetic HMG-CoA reductase inhibitor. Expert Opinions and Investigations in Drugs, 9, 2653-2661.
21. Kearney, A. S., Crawford, L. F., Mehta, S. C. and Radebaugh, G. W., 1993, The interconversion kinetics, equilibrium, and solubilities of the lactone and hydroxyacid forms of the HMG-CoA reductase inhibitor, CI-981. Pharmaceutical Research, 10, 1461-1465.
22. Kimata, H., Fujino, H., Koide, T., Yamada, Y., Tsunenari, Y., Yonemitsu, M. and Yanagawa, Y., 1998, Studies on the metabolic fate of NK-104, a new inhibitor of HMG-CoA reductase (1): Absorption, distribution, metabolism and excretion in rats. Xenobiotics and Metabolic Disposition, 13, 484-498.
23. Kojima, J., Fujino, H., Abe, H., Yoshimura, M., Kanda, H. and Kimata, H., 1999a, Identification of metabolites of NK-104, an HMG-CoA reductase inhibitor, in rat, rabbit and dog bile. Biological and Pharmacological Bulletin, 22, 142-150.
24. Kojima, J., Fujino, H., Yoshimura, M., Morikawa, H. and Kimata, H., 1999b, Simultaneous determination of NK-104 and its lactone in biological samples by column-switching high-performance liquid chromatography with ultraviolet detection. Journal of Chromatography (B), 724, 173-180.
25. Komai, T., Kawai, K., Tokui, T., Tokui, Y., Kuroiwa, C., Shigehara, E. and Tanaka, M., 1992, Disposition and metabolism of pravastatin sodium in rats, dogs and monkeys. European Journal of Drug Metabolism Pharmacokinetics, 17, 103-111.
26. Lennernas, H. and Fager, G., 1997, Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Clinical Pharmacokinetics, 32, 403-425.
27. Ludwig, E., Wolfinger, H. and Ebner, T., 1998, Assessment of microsomal tolbutamide hydroxylation by a simple thin-layer chromatography radioactivity assay. Journal of Chromatography (B), 707, 347-350.
28. Mackenzie, P. I., Owens, I. S., Burchell, B., Bock, K. W., Bairoch, A., Belaner, A., Fournel-Gigleux, S., Green, M., Hum, D. W., Iyanagi, T., Lancet, D., Louisot, P., Magdalou, J., Chowdhury, J. R., Ritter, J. K., Schachter, H., Tephly, T. R., Tipton, K. F. and Nebert, D. W., 1997, The UDP glycosyltransferase gene superfamily: Recommended nomenclature update based on evolutionary divergence. Pharmacogenetics, 7, 255-269.
29. Suzuki, H., Aoki, T. and Tamaki, T., 1999, Hypolipidemic effect of NK-104, a potent HMG-CoA reductase inhibitor, in guinea pigs. Atherosclerosis, 146, 259-270.
30. Suzuki, H., Yamazaki, H., Aoki, T. and Tamaki, T., 2001, Hypolipidemic effect of NK-104 and other 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors in guinea pigs. Arzneim Forsch/Drug Research, 51, 38-45.
31. Tukey, R. H. and Strassburg, C. P., 2000, Human UDP-glucuronosyltransferases: Metabolism, expression, and disease. Annual Reviews in Pharmacology and Toxicology, 40, 581-616.
32. Yamada, I., Fujino H., Shimada, S. and Yoneda, M., 2001, Studies on the metabolic fate of pitavastatin (NK-104), a new inhibitor of HMG-CoA reductase - Is the metabolism of pitavastatin in monkey similar to that in human? Xenobiotic Metabolism and Disposition, 16 (suppl.), 291.
33. Yamada, N., Saito, Y. and Akanuma, Y., 2000, Effect of itavastatin on lipid metabolism in NIDDM patients with hyperlipidemia. Atherosclerosis, 151, 48.